Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
11/2003
11/27/2003WO2002072095A3 Tiotropium salts for treating inflammatory diseases
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003WO2002056896A3 Treatment solution in addition to dressing material for caring for wounds
11/27/2003WO2002049625A3 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/27/2003US20030220489 29 human secreted proteins
11/27/2003US20030220480 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
11/27/2003US20030220468 Modified forms of pharmacologically active agents and uses therefor
11/27/2003US20030220375 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
11/27/2003US20030220371 Administering to a mammal an aromatic or heteroaromatic ring substituted triazole derivative to treat the conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, and obesity
11/27/2003US20030220367 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists
11/27/2003US20030220354 Quinazoline ditosylate salt compounds
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220349 Related to organ systems which respond to estrogen agonists or antagonists; in particular, 2-phenyl-3-aroylbenzothiophenes and 1-(alkylaminoethoxy phenyl)-1-phenyl-2-phenylbut-1-enes have wide application as estrogen agonists
11/27/2003US20030220347 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
11/27/2003US20030220345 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones
11/27/2003US20030220341 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
11/27/2003US20030220331 6-Azauracil derivatives as IL-5 inhibitors
11/27/2003US20030220330 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
11/27/2003US20030220322 Substituted 3,4-dihydro-pyrimido[1,2a]pyrimidines and 3,4-dihydro-pyrazino[1,2a]pyrimidines, and methods for their preparation and use
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
11/27/2003US20030220271 Motilide compounds
11/27/2003US20030220268 New phenylalanine derivatives
11/27/2003US20030220256 Truncated 24kDa basic fibroblast growth factor
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030219898 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
11/27/2003US20030219875 Albumin fusion proteins
11/27/2003US20030219873 Self-assembling recombinant papillomavirus capsid proteins
11/27/2003US20030219864 Novel variants of RANKL protein
11/27/2003US20030219465 Composition for delivery of dithranol
11/27/2003US20030219439 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
11/27/2003US20030219438 Human antibodies that bind human TNFalpha
11/27/2003US20030219437 Administering antibodies used as antagonists to CD antigen ligands on the cells, for prophylaxis of cardiovascular, gastrointestinal or urogenital disorders
11/27/2003US20030219401 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
11/27/2003US20030219393 Inhibitors of melanocyte tyrosinase as topical skin lighteners
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2486483A1 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
11/27/2003CA2486147A1 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486106A1 Compounds and methods for inhibiting selectin-mediated function
11/27/2003CA2485896A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
11/27/2003CA2485463A1 A direct cellular energy delivery system
11/27/2003CA2485214A1 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
11/27/2003CA2485212A1 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
11/27/2003CA2485081A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
11/27/2003CA2485012A1 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
11/27/2003CA2484702A1 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/27/2003CA2484646A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
11/27/2003CA2484631A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
11/27/2003CA2483190A1 External preparation for allergic diseases
11/27/2003CA2482756A1 Indole derivatives and the use thereof as cb<sb>2</sb> receptor ligands
11/27/2003CA2482746A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
11/27/2003CA2482348A1 Combinations of an ace inhibitor, a calcium channel blocker and a diuretic
11/26/2003EP1365028A1 Method for expression of PDGF or IGF proteins in yeast
11/26/2003EP1365024A1 Traf3-binding b cell-specific receptor
11/26/2003EP1364953A1 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
11/26/2003EP1364952A1 Bicyclic nitrogenous fused-ring compound
11/26/2003EP1364949A1 Jnk inhibitor
11/26/2003EP1364943A1 Novel cystine derivatives and inhibitors for the activation of inflammatory factors
11/26/2003EP1364651A1 Pharmaceutical composition with deswelling properties
11/26/2003EP1364642A1 Composition for delivery of dithranol
11/26/2003EP1364641A1 Use of at least one metal complex as a desquamative agent
11/26/2003EP1364069A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
11/26/2003EP1364051A2 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
11/26/2003EP1364023A2 Method of diagnosing and treating cartilage disorders
11/26/2003EP1363993A2 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)
11/26/2003EP1363914A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
11/26/2003EP1363913A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
11/26/2003EP1363910A2 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
11/26/2003EP1363909A2 Tricyclic androgen receptor modulator compounds
11/26/2003EP1363906A2 Heterocyclic inhibitors of erk2 and uses thereof
11/26/2003EP1363902A1 Chemical compounds
11/26/2003EP1363900A1 Isoindole-imide compounds as tnf-inhibitors
11/26/2003EP1363898A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/26/2003EP1363891A2 Anthrone derivatives and their use as jnk inhibitors
11/26/2003EP1363885A1 Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof
11/26/2003EP1363874A2 Tryptase inhibitors
11/26/2003EP1363702A1 Methods of inhibiting kinases
11/26/2003EP1363677A1 Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing
11/26/2003EP1363657A2 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
11/26/2003EP1363656A2 Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system
11/26/2003EP1363653A2 Methods and compositions for enhancing angiogenesis
11/26/2003EP1363650A2 AQUATIC ANIMAL TREATMENT METHOD AND COMPOSITION CONTAINING i PIMENTA /i EXTRACT
11/26/2003EP1363644A2 Modulation of gsk-3beta activity and its different uses
11/26/2003EP1363640A2 Nucleic acid derivatives
11/26/2003EP1363635A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
11/26/2003EP1363631A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/26/2003EP1363617A1 Cyanoacrylate compositions for prophylactic or therapeutic treatment of diseases manifesting themselves in and/or damaging cutaneous tissue
11/26/2003EP1363600A1 Liquid formulations for the prevention and treatment of mucosal diseases and disorders
11/26/2003EP1363594A1 Cosmetic formulations containing flavonoid derivatives
11/26/2003EP1363593A1 Free nicotine based cosmetic composition and uses thereof
11/26/2003EP1363585A2 Cosmetic or pharmaceutical agent
11/26/2003EP1363581A2 Pyrrolo(2,3-d)pyrimidine nucleoside analogs
1 ... 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 ... 1065